Euretina 2025 Conference Review

In this review:
  -  Interim results from the PERCEIVE study of voretigene neparvovec
  -  VP-001 in patients with PRPF31-related retinitis pigmentosa
  -  Longer durability new-generation therapies for neovascular AMD
  -  Gene therapy for neovascular AMD
  -  MacTel2: systemic associations
  -  Current and upcoming therapies for MacTel2
  -  H.A.L.T technology lenses slow progression of MOP
  -  Impact of fetal alcohol disorder on optical development
  -  AAVB-081 gene therapy for Usher syndrome type 1B retinitis pigmentosa
  -  Subretinal laru-zova gene therapy for X-linked retinitis pigmentosa

Please login below to download this issue (PDF)

Subscribe